Sequential therapy with cytarabine and bismuth-213 (Bi-213)-labeled-HuM195 (anti-CD33) for acute myeloid leukemia (AML) Meeting Abstract

  


Authors: Mulford, D. A.; Pandit-Taskar, N.; McDevitt, M. R.; Finn, R. D.; Weiss, M. A.; Apostolidis, C.; Morgenstern, A.; Divgi, C. R.; Larson, S. M.; Scheinberg, D. A.; Jurcic, J. G.
Abstract Title: Sequential therapy with cytarabine and bismuth-213 (Bi-213)-labeled-HuM195 (anti-CD33) for acute myeloid leukemia (AML)
Meeting Title: 46th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 104
Issue: 11 Pt. 1
Meeting Dates: 2004 Dec 4-7
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2004-11-16
Start Page: 496A
Language: English
ACCESSION: WOS:000225127501791
PROVIDER: wos
PUBMED: 15562524
DOI: 10.1182/blood.V104.11.1790.1790
Notes: Meeting Abstract: 1790 -- 46th Annual Meeting of the American-Society-of-Hematology -- DEC 04-07, 2004 -- San Diego, CA -- 1 -- Source: Wos
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Deborah Mulford
    8 Mulford
  2. Chaitanya Divgi
    163 Divgi
  3. Ronald D Finn
    279 Finn
  4. Michael R Mcdevitt
    144 Mcdevitt
  5. Joseph G Jurcic
    134 Jurcic
  6. Neeta Pandit-Taskar
    342 Pandit-Taskar
  7. David Scheinberg
    499 Scheinberg
  8. Steven M Larson
    958 Larson
  9. Mark Weiss
    86 Weiss
Related MSK Work